translation agency

NLM AIDSLINE
T-20--a fusion drug, first of several to come.

December 30, 1999
Treat Update. 1998 Dec;10(10):2. Unique Identifier : AIDSLINE

Researchers at Trimeris Inc. have developed and tested a small molecule, called T-20, which prevents HIV from attaching to cells. Preliminary results show a dramatic decline in HIV levels, and the drug appears to have low toxicity. T-20 is given via infusion, although other companies are developing similar compounds that can be taken through the nose. Study details and results are briefly described. Some concerns regarding T-20 include long term toxicity and its interaction with other drugs.

NEWSLETTER ARTICLE Anti-HIV Agents/*PHARMACOLOGY Dose-Response Relationship, Drug Drugs, Investigational HIV Envelope Protein gp41/*PHARMACOLOGY HIV Infections/*DRUG THERAPY/VIROLOGY HIV-1/DRUG EFFECTS/PHYSIOLOGY Human Infusions, Intravenous Male Peptide Fragments/PHARMACOLOGY Viral Load Virus Replication/*DRUG EFFECTS

www.aegis.org